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Introduction: Chronic angiotensin converting enzyme inhibitor (ACEIs) treatment can suppress
arrhythmogenesis. To examine whether the effect is more immediate and independent of suppression
of pathological remodelling,we tested the antiarrhythmic effect of short-termACE inhibition in healthy
normotensive rats.
Methods and results:Wistar rats were administered with enalaprilat (ENA, i.p., 5 mg/kg every 12 h)
or vehicle (CON) for twoweeks. Cellular shortening was measured in isolated, electrically paced car-
diomyocytes. Standard 12-lead electrocardiography was performed and, hearts of anesthetized open-
chest rats were subjected to 6-min ischemia followed by 10-minute reperfusion to examine suscepti-
bility to ventricular arrhythmias. Expressions of calcium regulating proteins (SERCA2a, cardiac sarco/
endoplasmic reticulum Ca2+-ATPase; CSQ, calsequestrin; TRD, triadin; PLB, phospholamban;
FKBP12.6, FK506-binding protein) were measured by Western blot and mRNA levels of L-type
calcium channel (Cacna1c), ryanodine receptor (Ryr2) and potassium channels Kcnh2 and Kcnq1
were measured by qRT-PCR. ENA decreased systolic as well as diastolic blood pressure (by 20%,
and by 31%, respectively, for both P,0.05) but enhanced shortening of cardiomyocytes at basal con-
ditions (by 34%, P,0.05) and under beta-adrenergic stimulation (by 73%, P,0.05). Enalaprilat shor-
tened QTc interval duration (CON: 78+1 ms vs. ENA: 72+2 ms; P,0.05) and significantly
decreased the total duration of ventricular fibrillations (VF) and the number of VF episodes
(P,0.05). Reduction in arrhythmogenesis was associated with a pronounced upregulation of
SERCA2a and increased Cacna1c mRNA levels.
Conclusion: Short-termACEI treatment canprovideprotection against I/R injury-inducedventricular
arrhythmias in healthy myocardium and this effect is associated with increased SERCA2a expression.
CON ENA
Calcium regulating proteins
SERCA2a 100+20 304+13*
CSQ 100+6 105+7
TRD 100+16 117+10
PLB 100+9 109+16
FKBP12 100+12 93+7
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